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Available online 21 June 2013Abstract O-linked-N-acetylglucosamine (O-GlcNAc), a post translational modification, has emerged as an important cue in
controlling key cell mechanisms. Here, we investigate O-GlcNAc's role in the maintenance and differentiation of human
pluripotent stem cells (hPSC). We reveal that protein expression of O-GlcNAc transferase and hydrolase both decreases during
hPSC differentiation. Upregulating O-GlcNAc with O-GlcNAc hydrolase inhibitors has no significant effect on either the
maintenance of pluripotency in hPSC culture, or the loss of pluripotency in differentiating hPSC. However, in spontaneously
differentiating hPSC, excess O-GlcNAc alters the expression of specific lineage markers: decrease of ectoderm markers (PAX6
by 53–88%, MSX1 by 26–49%) and increase of adipose-related mesoderm markers (PPARγ by 28–100%, C/EBPα by 46–135%). All
other lineage markers tested (cardiac, visceral-endoderm, trophectoderm) remain minimally affected by upregulated
O-GlcNAc. Interestingly, we also show that excess O-GlcNAc triggers a feedback mechanism that increases O-GlcNAc hydrolase
expression by 29–91%. To the best of our knowledge, this is the first report demonstrating that excess O-GlcNAc does not affect
hPSC pluripotency in undifferentiated maintenance cultures; instead, it restricts the hPSC differentiation towards specific cell
lineages. These data will be useful for developing targeted differentiation protocols and aid in understanding the effects of
O-GlcNAc on hPSC differentiation.
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Human pluripotent stem cells (hPSC), comprising of human
embryonic stem cells (hESC) (Thomson et al., 1998) and induced
pluripotent stem cells (iPSC) (Takahashi and Yamanaka, 2006),
are able to proliferate ad infinitum, differentiate into cells of
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teratomas when transplanted into immunosuppressed mice.
Owing to these unique properties, hPSC hold great promise for
regenerative medicine (Grabel, 2012). However, before hPSC
can be clinically relevant, cues controlling pluripotency and
differentiation need to be clearly understood. Pluripotency and
differentiation cues are diverse (Bratt-Leal et al., 2009) and
include soluble factors, extracellular matrix–cell interactions,
cell–cell interactions, and intracellular signals such as phos-
phorylation (Van Hoof et al., 2009) and glycosylation (Cheray et
al., 2011). Even though surface glycans have been shown to
play an active role in the maintenance of undifferentiated
stem cells (Yagi et al., 2012), the contribution of O-linked-
N-acetylglucosamine (O-GlcNAc), a specific post-translational
modification found on serine and threonine residues of
cytoplasmic and nucleus proteins (Torres and Hart, 1984), to
stem cell mechanisms remains largely unknown.
O-GlcNAc is added and removed by two enzymes, O-GlcNAc
transferase (OGT) (Haltiwanger et al., 1992) and O-GlcNAc
hydrolase (OGA) respectively (Dong and Hart, 1994). OGT and
OGA enzymes are able to change O-GlcNAcylation level at a
faster rate than the rate of the protein backbone turnover (Chou
et al., 1992). O-GlcNAc is hence a reversible and dynamic
modification that allows O-GlcNAc to regulate protein
functions at the cellular level. Increasingly, reports show
that O-GlcNAc controls the function of proteins involved in a
variety of cellular processes such as signaling (Zachara and
Hart, 2006), cell cycle (Fong et al., 2012), stress response
(Hart and Akimoto, 2009), gene transcription and develop-
ment. In zebrafish development, OGT overexpression resulted
in morphological defect in early embryo (Webster et al., 2009).
In addition, OGT knockout was lethal in mouse embryonic stem
cells (mESC) (Shafi et al., 2000). Further studies in mESC
showed that an essential pluripotent stem cell transcription
factor, Oct4, is modified and controlled by O-GlcNAc and excess
O-GlcNAc increases mESC pluripotency and prevented differ-
entiation (Jang et al., 2012). This concurs with another study
showing that mESC with excess O-GlcNAc had decreased ability
to differentiate towards the cardiac lineage (Kim et al., 2009).
Even though these reports have started to shed light on
the relationship between O-GlcNAc and mESC, to the best of
our knowledge, there hasn't been any published study on the
role of O-GlcNAc in hPSC. Mouse and human ESC are well
known to differ due to differences in species and techniques
used to isolate the cells (Van Hoof et al., 2006). Several reports
have shown that mESC and hESC use different mechanisms to
maintain pluripotency (Greber et al., 2010) and to differenti-
ate (Odorico et al., 2001). For example, leukemic inhibitor
factor is required for mESC culture but not for hESC (Ginis et
al., 2004). In addition, trophoblast lineage cannot be derived
from mESC differentiation but can be obtained from hESC
differentiation (Douglas et al., 2009).
Here, we investigated the effect that O-GlcNAc has on the
maintenance of pluripotency and directing differentiation of
both hESC and iPSC. We revealed that, in contrast to mESC,
O-GlcNAcylation does not have a significant effect on hESC
pluripotency maintenance. Instead, we report that O-GlcNAc
is involved in hPSC differentiation mechanism. Excess
O-GlcNAcylation level decreases ectoderm commitment and
increases adipose-related mesoderm lineage of hPSC. Inter-
estingly, increasing O-GlcNAcylation level also triggers a
counter-mechanism to balance the upregulation of O-GlcNAc.Materials and methods
Chemicals
PUGNAc (Sigma-Aldrich) and Thiamet G (Tocris Bioscience)
were solubilized in water and DMSO respectively. In the
feeding experiments, PUGNAc and Thiamet G were added in
the culture media at a final concentration of 100 μM and
42 μM respectively. Appropriate controls with addition of
water or DMSO only were used.Cell culture
Human embryonic stem cell line, HES-3 (46 X,X) (ES Cell
International), was cultured as described previously (Choo
et al., 2006). Briefly, hESC were seeded on Matrigel (BD
bioscience)-coated tissue culture dishes and maintained at
37 °C under 5% CO2 with conditioned media. Conditioned
media were harvested from mitomycin-C (Sigma) treated
immortalized mouse embryonic fibroblast cultured with KO
media supplemented with 10 ng/mL fibroblast growth
factor-2. KO medium was composed of Knockout™ DMEM
supplemented with 20% Knockout™ serum replacement,
0.1 mM MEM non-essential amino acid, 2 mM L-glutamine,
1× penicillin streptomycin, and 1× 2-mercaptoethanol.
Weekly, hESC were routinely passaged mechanically using
StemPro® EZPassage™ (Life Technologies). For the feeding
experiment, conditioned media were supplemented with
100 μM PUGNAc and fed to the cultures daily.
Induced pluripotent stem cells, ESIMR90 and ES4SKIN,
reprogrammed respectively from fetal lung fibroblast (IMR-
90) and neonatal foreskin fibroblast were kindly provided by
Prof. James Thomson (Genome Centre of Wisconsin). The iPSC
were cultured at 37 °C under 5% CO2 on hESC-qualified Matrix
(BD bioscience) with conditioned media supplemented with
100 ng/mL fibroblast growth factor-2. Weekly, iPSC were
routinely passaged mechanically using StemPro® EZPassage™
(Life Technologies).
Fetal lung fibroblast, IMR-90 (CCL-186™), and neonatal
foreskin fibroblast (CRL-2522™) were obtained from ATCC.
The fibroblasts were cultured at 37 °C under 5% CO2 with
DMEM high glucose media supplemented with 10% fetal bovine
serum (Thermo Scientific), 25 U/mL penicillin, 25 μg/mL
streptomycin, and 2 mM L-glutamine.
Unless stated, all culture medium components were
obtained from Life Technologies.Differentiation
To induce spontaneous differentiation, hESC or iPSC were
harvested as clumps using StemPro® EZPassage™ (Life
Technologies). The clumps were cultured as embryoid bodies
(EB) in an ultra-low attachment plate (Corning) supplied
with EB-medium. EB-medium was composed of Knockout™
DMEM supplemented with 20% fetal bovine serum (Thermo
Scientific), 25 U/mL penicillin, 25 μg/mL streptomycin, 2 mM
L-glutamine, 0.1 mMNEAA and 0.1 mM 2-mercaptoethanol. EB
medium was routinely replaced with fresh medium every
2 days. After 7 days of differentiation, the EB were seeded on
gelatinized culture dishes.
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PUGNAc. PUGNAc was added 24 h after differentiation induc-
tion. Subsequently, the EB medium supplemented with 100 μM
PUGNAc was refreshed every odd days. Alternatively 42 μM of
Thiamet G was used instead of PUGNAc.
Neuroprogenitors generated from hESC by directed differ-
entiation were obtained as previously described (Bardy et al.,
2013;Wu et al., 2012). Briefly, hESCwere harvested as clumps
using StemPro® EZPassage™ and cultured as EB in an ultra-low
attachment plate supplied with EB-medium for 3 days. EB
cells were then seeded on laminin-coated plates and cultured
in N2B27 medium (DMEM/F-12 GlutaMAX™, 1× N2 supplement,
1× B-27®minus Vitamin A, 1% non-essential amino acids, 1 mM
L-glutamine, 25 U/mL 2-β-mercaptoethanol) supplemented
with 500 ng/mL of recombinant human Noggin Fc Chimera
(R&D Systems) for 10 days (medium was routinely refreshed
every 2 days). Thereafter, cells were harvested as clumps and
cultured in an ultra-low attachment plate supplied with N2B27
medium supplemented with 20 ng/mL epidermal growth
factor (EGF) (Peprotech) and 20 ng/mL fibroblast growth
factor-2 (FGF-2) for 7 days (medium was routinely refreshed
every 2 days). Neurospheres obtained here were seeded on
laminin-coated plates and cultured with N2B27 medium
supplemented with EGF and FGF-2. Two days after seeding,
N2B27mediumwas replacedwith freshmedium supplemented
with EGF, FGF-2 and 100 μM PUGNAc. Cells were harvested for
real-time qRT PCR analysis 24 h after PUGNAc treatment.
Unless stated, all culture medium components were
obtained from Life Technologies.
Flow cytometry analysis
For FACS analysis, 2 × 105 cells were harvested by trypsin (Life
Technologies) treatment and washed with cold washing
solution (1% BSA in PBS). Cells were treated by 100 μL of
fixation medium (Life Technologies) for 15 min. After wash-
ing, cells were treated with 100 μL of permeabilization
medium (Life Technologies) for 15 min in the presence of
primary antibodies (see Supporting Information Table 1 for the
supplier information). The following amounts of antibodies
were used: 5 μL of anti-OCT4, 2 μL of anti-TRA-1-60, and 1 μL
of anti-SSEA4 for 100 μL of permeabilization medium. After
washing, cells were incubated for 15 min with fluorescein
isothiocyanate-conjugated secondary antibodies (Dako, 1:500
dilution). After a final wash, cells were resuspended in 200 μL
of washing solution and analyzed by FACScan (Becton
Dickinson FACS Calibur).
Western blot and Eastern blot
Proteins were harvested with the following lysis buffer: 1%
Igepal, 50 mM Tris–HCl, and 150 mM NaCl, pH 7.4
supplemented with complete protease inhibitor cocktail
(Roche). When needed, PUGNAc to a final concentration of
50 μM, was added to the lysis buffer to preserve O-GlcNAc
modifications. After protein quantification using 660 nm
protein assay (Thermo Scientific), 20 μg of protein extract
was separated by SDS-PAGE electrophoresis and later on
transferred onto PVDF membranes. PVDF membranes were
blocked for 1 h at room temperature by Odyssey blocking
buffer (LI-COR) and incubated overnight at 4 °C withprimary antibodies (see Supporting Information Table 1 for
details). The antibodies were diluted as indicated in a
solution containing one part Odyssey blocking buffer and
one part 0.05% Tween® 20 in PBS. To visualize post-
translational modifications, Eastern blots were prepared
similarly to Western blots and detected using an anti-
O-GlcNAc antibody (Supporting Information Table 1). Blots
were finally developed using peroxidase-conjugated sec-
ondary antibodies (Dako; 1:10,000 dilution) and visualized
with ECL prime western blotting detection reagent (GE
Healthcare Life Sciences). Alternatively, blots were also
developed using fluorescent-conjugated secondary anti-
bodies (LI-COR, 1:20,000 dilution) and visualized by an
ODYSSEY® imaging system (LI-COR). Band intensity was
measured by densitometry using GelQuant software (Biochem
Lab Solutions). Band intensity expression differences (Δ*) were
calculated at the time point (*) presenting the greatest
difference between the test experiment (+) and the control
(−):
Δ; PAX6 ¼
X PAX6;þð Þ
X ACTIN;þð Þ−
X PAX6;−ð Þ
X ACTIN;−ð Þ
X PAX6;−ð Þ
X ACTIN;−ð Þ
 100:
Real-time qRT-PCR
Total mRNAs were extracted from cells using RNeasy®
MiniKit (Qiagen) according to the manufacturer's instruc-
tions. Then, cDNAs were produced using a SuperScript™ III
First-Strand synthesis system for RT-PCR (Life Technolo-
gies) according to the manufacturer's protocol. Real-time
quantitative reverse-transcription polymerase chain reac-
tion (qRT-PCR) was performed using Power SYBR green
(Applied Biosystems) and 7500 Real time PCR system
(Applied Biosystems). Specific primers used are listed in
Supporting Information Table 2. Expression differences (Δ*)
were calculated at the time point (*) presenting the
greatest difference between the test experiment (+) and
the control (−):
Δ ¼ X þð Þ−X −ð Þ
X −ð Þ  100:
Additional protocols
Additional information related to the identification of hESC
O-GlcNAcylated proteins after immunoprecipitation can be
found in the Supporting Information section. As reported, a
proteomic approach has been used for such identification.
Results
O-GlcNAc transferase and hydrolase expression
during differentiation
We first determined the expression of OGT and OGA in
undifferentiated cells, differentiating cells and terminally
differentiated cells (Fig. 1). From undifferentiated hESC to
929Excess O-GlcNAc modifies human pluripotent stem cell differentiationdifferentiating hESC embryoid bodies (EB), there was a
marked decrease in OGT and OGA protein expressions
(Fig. 1). OGT and OGA expressions in iPSC ESIMR90 and
ES4SKIN were also higher than in their parental cells
(IMR-90 and Foreskin respectively) prior to reprogramming.
Overall, OGT and OGA protein expressions were found to
significantly decrease during the differentiation of hPSC.
Our results are consistent with previous reports showing a
similar decrease in OGT expression during zebrafish embryo-
genesis (Webster et al., 2009) and mESC differentiation (H. S.
Kim et al., 2009).
We then determined the level of O-GlcNAc during hPSC
differentiation. Global level of O-GlcNAcylation was deter-
mined in undifferentiated, differentiating and terminally
differentiated cells using a specific antibody against O-GlcNAc
(CTD110.6) (Comer et al., 2001) (Fig. 1). We observed noFigure 1 Western and Eastern blot analyses of pluripotent cells (hE
day 21 post-differentiation; and terminally differentiated fibroblas
proteins differentially expressed between undifferentiated and termstriking difference on the overall O-GlcNAcylation level during
hPSC spontaneous differentiation; this was expected as both
OGT and OGA decrease during differentiation. Our result on
O-GlcNAcylation level differs from previous reports showing
O-GlcNAcylation fluctuation in Xenopus laevis embryogenesis
(Dehennaut et al., 2008); and O-GlcNAcylation decreases
during mESC differentiation (Kim et al., 2009). This apparent
inconsistency might be explained by inherent differences
between mouse and human PSC in term of species and
pluripotency ability (Schnerch et al., 2010). Even though the
overall O-GlcNAcylation was comparable between samples,
differences were observed on specific O-GlcNAc modified
proteins during differentiation (Fig. 1 arrowheads). Some
O-GlcNAc modified proteins seemed more abundant in
either undifferentiated or differentiated cells. These results
suggest that different O-GlcNAc modified proteins contributeSC, ESIMR90, ES4SKIN); hESC embryoid bodies (EB) at day 14 and
ts (Foreskin, IMR-90). Arrowheads point at O-GlcNAc modified
inally differentiated cells.
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differentiation.
To confirm the reliability of the anti-O-GlcNAc antibody
(CTD110.6) used here, hESC O-GlcNAcylated proteins were
immunoprecipitated and identified by mass spectrometry
using a proteomic-based approach. As expected, some of our
identified O-GlcNAcylated proteins (Supporting Information
Table 3) have previously been reported as O-GlcNAc
modified in other cell types (CARM1 (Cheung et al., 2008),
HSPD1 (Kim et al., 2006)). In addition, some proteins have
also been reported as important for either pluripotency
(CARM1, HSPD1, MYH9) or differentiation (GSTP1, PHGDH,
CCT3) (see Supporting Information Table 3 for details and
references) further suggesting the importance of O-GlcNAc
for hESC.Inhibitors to alter O-GlcNAc level in
differentiating hESC
To determine if O-GlcNAc is important for the maintenance
of pluripotency and differentiation, we tested in cell culture
the efficiency of OGA inhibitors, PUGNAc (Haltiwanger et
al., 1998) and Thiamet G (Yuzwa et al., 2008), to increase
O-GlcNAcylation level. PUGNAc, used to a final concentra-
tion of 100 μM (as previously used in other cell lines (Zachara
et al., 2011; Park et al., 2005)), was able to efficiently
increase O-GlcNAcylation level in cultured hESC and sponta-
neously differentiating hESC EB (Fig. 2). For Thiamet G, a
working concentration of 42 μM (equivalent to 100 μM of
PUGNAc) was chosen, based on the reported inhibition
constant (Ki) of the inhibitors (50 nM and 21 nM for PUGNAc
and Thiamet G respectively) (Macauley and Vocadlo, 2010).
Similar to PUGNAc, Thiamet G was able to efficiently
increase O-GlcNAcylation level in hESC EB (Fig. 2). Hence,
for all subsequent feeding experiments, the concentrations
of PUGNAc and Thiamet G used were maintained at a final
concentration of 100 μM and 42 μM respectively.Figure 2 Eastern blot analysis of hESC and hESC EB suppleEffect of PUGNAc on hESC pluripotency
Next, we investigated the effect of altering O-GlcNAc
level on the routine culture of hESC. We maintained
hESC with the addition of 100 μM of PUGNAc to in-
crease O-GlcNAcylation level. After 2 weeks of culture,
even though the O-GlcNAcylation level was up-regulated
(Supporting Information Fig. 1A), the expression of the
three pluripotency markers tested (OCT4, TRA-1-60, SSEA
4) remained identical by FACS analysis (Fig. 3). Similarly,
the protein expression of additional pluripotency markers
(SOX2, NANOG) remained comparable by Western blot
analysis (Supporting Information Fig. 1B). All together,
these data suggest that O-GlcNAc level is not involved in
the maintenance of hESC pluripotency.Effect of PUGNAc on hESC differentiation
Then, we investigated if altering O-GlcNAcylation level
would have an effect on hESC differentiation. We chose to
spontaneously differentiate hESC as EB because it allows
hESC to differentiate into any cell lineage (Itskovitz-Eldor et
al., 2000). Hence, hESC EB were treated with PUGNAc to
increase O-GlcNAcylation level and the expression of
pluripotent and differentiation markers was monitored.
After PUGNAc treatment, ectoderm marker (PAX6, MSX1)
mRNA (Fig. 4A) and protein (Fig. 4B) expressions were
significantly decreased following PUGNAc treatment. Those
results were also confirmed by the mRNA expression of five
additional ectoderm markers, SOX1, MAP2, NEUROGENIN-2,
TBR2 and LHX3 (Supporting Information Fig. 2A). Similar to
ectoderm, early-mesendoderm markers (BRACHYURY, TBX6,
FOX2A, CER1, GSC) showed a decrease in mRNA expression
at day 4 (Supporting Information Fig. 2B) and showed
an even stronger decrease at day 2 (Supporting Information
Fig. 2C). In addition, signaling proteins which are known to
drive early-mesendoderm (NODAL, WNT3A) transcriptionallymented with 100 μM of PUGNAc or 42 μM of Thiamet G.
Figure 3 FACS analysis of hESC supplemented with 100 μM of PUGNAc for 1 and 2 weeks. Gray curves and white curves are
respectively samples non-incubated and samples incubated with primary antibodies. Doted lines mark the fluorescence peak for each
individual FACS analysis.
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PUGNAc suggesting that those signaling proteins might
actually drive the observed early-mesendoderm decrease.
In spite of the observed global reduction on early-
mesendoderm, some specific markers of mesoderm and
endoderm didn't follow the same trend. Adipose-related
mesoderm markers were found to increase transcriptionally
after PUGNAc treatment: PPARγ, C/EBPα (Fig. 4A); and LPL,
AP2 (Supporting Information Fig. 2A). Those results were
confirmed by PPARγ protein expression (Fig. 4B).
In contrast to ectoderm and adipose-related mesoderm
lineages, other specific lineages tested were minimally
affected by excess of O-GlcNAcylation. mRNA expressions
of visceral-related endoderm markers (GATA6, AFP),
cardiac-related mesoderm markers (HAND1, NKX2.5),trophectoderm markers (CDX2, BMP4), and pluripotency
markers (OCT4, NANOG) did not present any significant
changes (Supporting Information Fig. 2D). The downregulation
of OCT4 protein expression was also unaltered by treatment
with PUGNAc (Supporting Information Fig. 2E). These results
suggest that O-GlcNAc level does not affect the rate of
pluripotency loss during hESC differentiation.
Interestingly, expression of OGT and OGA was altered by
PUGNAc treatment. By increasing O-GlcNAcylation level,
mRNA (Fig. 4A) and protein (Fig. 4B) expressions decreased
for OGT and increased for OGA. These results suggest the
existence of an interplay between O-GlcNAc level and
enzymes regulating O-GlcNAc where a feed-back loop is
triggered such that O-GlcNAc has the ability to control the
expression of its own transferase and hydrolase enzymes.
Figure 4 hESC EB were treated with 100 μM of PUGNAc for 12 days. Differentiation was monitored by (A) real-time qRT-PCR and (B)
Western and Eastern blots. Expression differences (Δ*) were calculated as indicated in Materials and methods.
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resulted in a constant increase in O-GlcNAcylation level
during the 12 days of differentiation (Fig. 4B).
To confirm that the decrease in ectoderm marker expres-
sion was not restricted to hESC spontaneous differentiation,neuroprogenitors were derived from hESC using a directed
differentiation strategy previously described. As before, the
cells were incubated with PUGNAc but only for 24 h. As
expected, pluripotency marker (OCT4) decreased transcrip-
tionally upon directed differentiation (Supporting Information
Figure 5 hESC EB were treated with 42 μM of Thiamet G for
12 days. Differentiation was monitored by real-time qRT-PCR.
Expression differences (Δ*) were calculated as indicated in
Materials and methods.
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transcriptionally with an expression difference ranging
from 10 to 3000 fold (data not shown); consistently with
increases previously reported for neuroprogenitors from
hESC directed differentiation (Bardy et al., 2013; Wu et
al., 2012). PUGNAc treatment of neuroprogenitors led to
mRNA decrease of: PAX6, SOX1, NEUROGENIN-2, TBR2 and
LHX3 (Supporting Information Fig. 3). PUGNAc treatment
also triggered a decrease in transcription expression of
OGT and increase of OGA (Supporting Information Fig. 3).
The effect of PUGNAc on neuroprogenitors from hESC
directed differentiation therefore confirmed the data
obtained with hESC spontaneous differentiation.
Effect of Thiamet G on hESC differentiation
To rule out the possibility that our results were attributable to
PUGNAc side effect, we repeated the experiment using
another O-GlcNAc hydrolase inhibitor, Thiamet G. On the
whole, treatment with Thiamet G resulted in trends similar to
those observed with PUGNAc: i.e. decrease in ectoderm and
increase in adipose commitments (Fig. 5). Thiamet G also
resulted in an increase in OGA expression (Fig. 5). In addition,
Thiamet G had no effect on the rate of pluripotency marker
loss (OCT4); and had a minimal effect on the expression of
other tested lineage markers (GATA6, HAND1, CDX2; Sup-
porting Information Fig. 4).
Effect of PUGNAc on iPSC differentiation
To demonstrate that the effect of increasing O-GlcNAc on
differentiation was not limited to hESC but more broadly
applicable to hPSC, we extended our studies to include iPSC
(ESIMR90). Similar to hESC, iPSC were differentiated as EB
with addition of PUGNAc to increase O-GlcNAcylation level.
The increase of O-GlcNAcylation led to mRNA expression
changes in ectoderm, adipose-related mesoderm and early-
mesendoderm similar to the changes observed previously
with hESC (Fig. 6 and Supporting Information Fig. 5).
O-GlcNAc hydrolase mRNA expression was also decreased,
as previously demonstrated in hESC. Other tested lineage
markers (OCT4, GATA6, HAND1, CDX2) were minimally
affected by PUGNAc treatment (Supporting Information
Fig. 5).
Discussion
Since its discovery in 1984, O-GlcNAc has been linked to
many diseases (cancer (T. Chou and Hart, 2001), diabetes
(Issad et al., 2010), Alzheimer disease (Dias and Hart, 2007))
and key cell mechanisms: signaling (Zachara and Hart,
2006), cell cycle (Fong et al., 2012), stress response (Hart
and Akimoto, 2009), gene transcription and development.
Figure 6 iPSC (ESIMR90) EB were treated with 100 μM of
PUGNAc for 12 days. Differentiation was monitored by real-time
qRT-PCR. Expression differences (Δ*) were calculated as
indicated in Materials and methods.
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pluripotency maintenance and differentiation commitment
of hPSC.
We first showed that the expression of both OGT and
OGA decreased during hPSC differentiation, suggesting
that a high level of both OGT and OGA might be important
for pluripotency maintenance. Maintaining such a high
expression of both OGT and OGA may allow pluripotent
cells a high dynamic potential to rapidly add and remove
O-GlcNAc on specific proteins, thereby fine-tuning the
level of O-GlcNAc modified-proteins involved in regulating
pluripotency and self-renewal. Beside OGT and OGA, we
revealed that O-GlcNAcylation level remained relatively
constant during differentiation. Importantly, increasing
O-GlcNAcylation level neither affected the maintenance
of hESC pluripotency nor the loss of pluripotency during
hPSC differentiation. Our data seem to indicate that
further increase in O-GlcNAc level is not important for
hPSC pluripotency.
We then demonstrated that hPSC ectoderm differentia-
tion was inhibited upon upregulation of the O-GlcNAcylation
level (Table 1). In accordance with our results, increasing
O-GlcNAcylation level was reported to impair chicken axon
branching (Francisco et al., 2009) and mouse neuroepithelial
cell number and growth (Yanagisawa and Yu, 2009). The
authors suggested that the decrease in neuroepithelial cell
number could be attributed to the activation of cell death
signaling through O-GlcNAc modification (Yanagisawa and
Yu, 2009). However, based on our results, the link between
O-GlcNAc and cell death might be more complex in hPSC. By
increasing O-GlcNAcylation, hPSC differentiations towards
some lineages were unaffected and adipose lineage was even
promoted. In addition, in our feeding experiments using OGA
inhibitors such as PUGNAc and Thiamet G, we did not observe
any significant effect on hPSC cell viability (data not shown).
Our data suggest that O-GlcNAcmight not be directly linked to
hPSC EB cell death or that this link is stronger towards the
ectoderm lineage.
Apart from ectoderm commitment, we also found that
increasing O-GlcNAcylation level was able to enhance the
differentiation towards adipose-related mesoderm lineage
(Table 1). Our data complements a previous report showing
that O-GlcNAcylation level increases during murine adipo-
cyte differentiation (Ishihara et al., 2010). In addition,
PPARγ and C/EBPα, adipose-related transcription factors,
were previously reported to be modified and controlled by
O-GlcNAc in mouse cells (Ji et al., 2011; Li et al., 2009). As
we showed that O-GlcNAc controls PPARγ and C/EBPα mRNA
expressions, we infer that gene upstream of PPARγ and C/EBPα
may also be regulated by O-GlcNAc. O-GlcNAcylation effect on
adipose differentiation might be explained by the fact that
O-GlcNAc is used as glucose level sensor by cells (Issad and Kuo,
2008). Therefore by up-regulating O-GlcNAc level, stem cells
might sense high glucose availability and respond by increasing
differentiation towards adipose.
Table 1 Summary of PUGNAc and Thiamet G effects in hPSC.
hESC iPSC
Increase
+PUGNAc +Thiamet G +PUGNAc
Decrease
Protein mRNA mRNA mRNA
Ectoderm
PAX6
−82% −80% −88% −53%
MSX1
−54% −33% −26% −49%
Adipose
PPARγ +36% +28% +100% +50%
C/EBPα +46% +135% +61%
O-GlcNAc enzymes 
OGT
−74% −36% −31% +98%
OGA +102% +29% +51% +91%
935Excess O-GlcNAc modifies human pluripotent stem cell differentiationFurthermore, some of the hESC O-GlcNAcylated proteins
identified in this study have previously been reported to be
involved in adipose (GSTP1 (Jowsey et al., 2003)) and neural
differentiation (PHGDH (Kawakami et al., 2009), CCT3
(Matsuda and Mishina, 2004)) supporting our observed link
between O-GlcNAc and ectoderm, adipose differentiation.
Interestingly, we also demonstrated that increasing
O-GlcNAcylation level increased OGA expression in hPSC
and decreases OGT expression in hESC (Table 1). Our data
suggest the existence of a feedback loop based on OGA and
OGT expressions to balance O-GlcNAc excess. Such feedback
loops are known to exist between kinases and phosphoryla-
tion, and are important to control kinase activity (Roskoski,
2005; Adams, 2003).
Our data in human PSC differ from Jang H. et al.'s results
in mouse PSC (Jang et al., 2012). Indeed, in this parti-
cular publication, the authors showed that a high level of
O-GlcNAcylation maintains mESC pluripotency state and
inhibits differentiation for all germ layers. Our results
suggest a more complex function for O-GlcNAcylation in
human PSC. Similar to mESC, we show that in hPSC, high
level of O-GlcNAcylation indeed inhibits differentiation towards
ectoderm and early-mesendoderm. However, in contrast to
mESC, O-GlcNAc does not appear to affect visceral-related
endoderm and cardiac-related mesoderm differentiation in
hPSC. Moreover, high level of O-GlcNAcylation increases
hPSC differentiation towards adipose-related mesoderm.
Whereas high level of O-GlcNAcylation enhances mESC
pluripotency, excess O-GlcNAcylation does not signifi-
cantly affect the expression of pluripotent markers in
hESC. Overall, the comparison of Jang H. et al' s results
and our results suggests that O-GlcNAcylation plays
different roles in mouse and human PSC.
As excess of O-GlcNAc specifically enhances hPSC differen-
tiation towards adipose lineage, our results might prove
relevant for the development of hPSC differentiation proto-
cols and commercial applications. A current strategy for hPSC
application consists of expanding hPSC and differentiating
them towards mesenchymal stem cells (MSC) (Hematti, 2011).
Those hPSC derived MSC could become a well characterized
and homogenous cell source for diverse applications: cancer
treatment (Bak et al., 2011), drug screening (Cressey, 2012)and regenerative medicine (Karlssson et al., 2009). hPSC
derived adipose MSC, in particular, hold a great potential for
regenerative medicine because of their ability to differentiate
towards various cell lines such as hepatocytes (Aurich et al.,
2009), pancreatic endocrine (Silva et al., 2012), osteoblasts
(Mihaila et al., 2012) and cardiomyocytes (Chang et al., 2012).
Such strategies could rely on O-GlcNAc upregulation as a
temporary and genetic modification-free method to increase
the amount of hPSC-derived adipose MSC.Conclusion
To the best of our knowledge, this is the first study
investigating the effect of O-GlcNAc in hPSC. Here, we
demonstrated that O-GlcNAcylation level alters the differ-
entiation towards ectoderm and adipose lineages and that
O-GlcNAc level is not essential for maintaining pluripotency
of hPSC. Our data suggests that O-GlcNAc is an important
regulator of hPSC differentiation towards specific lineages.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.06.004.
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